Rather than ‘can we cure?’ (hepatitis C), the question is now ‘who should we cure first?’. This question is driven partly by the prohibitively high cost of Direct-acting anti-viral (DAAs) treatment. If DAAs were cheap, then anyone who wanted treatment would be given treatment—but that is not the current reality. . . .
. . . The answer to the question of who to cure ‘first’ may also be driven, in part, by the stigma and discrimination associated with injecting drugs
Anneke S. de Vos, Maria Prins and Mirjam E. E. Kretzschmar in Addiction